• Explore /
  • Poster
  • / DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.

DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.

Abstract Poster

Authors

Enrique Grande

Enrique Grande

MD Anderson Cancer Center Madrid, Madrid, Spain

Enrique Grande , Félix Guerrero , Javier Puente , Isabel Galante , Ignacio Duran , Javier Fuentes , Teresa Alonso-Gordoa , Javier Burgos , Albert Font Pous , Oscar Buisan , Alvaro Pinto , Mario Alvarez-Maestro , Oscar Reig Torras , Pablo Maroto , Xavier Garcia del Muro , Patricia Galvan , Nuria Malats , Aleix Prat , Francisco X. Real , Daniel E. Castellano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT03472274

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS4588)

DOI

10.1200/JCO.2019.37.15_suppl.TPS4588

Abstract #

TPS4588

Poster Bd #

413a

Abstract Disclosures

Similar Posters

First Author: Matt D. Galsky

First Author: Thomas Powles

First Author: Ghassan K. Abou-Alfa

First Author: Deepak Kilari